Open AccessLiver Resection as Part of Cytoreductive Surgery for Ovarian Cancer
Author(s) -
Jorge LunaAbanto,
Luis García Ruíz,
J.L. Quesada Martínez,
M Alvarez Larraondo,
Vladimir Villoslada Terrones
Publication year - 2020
Publication title -
journal of gynecologic surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.133
H-Index - 15
eISSN - 1557-7724
pISSN - 1042-4067
DOI - 10.1089/gyn.2019.0074
Subject(s) - medicine , cytoreductive surgery , surgery , ovarian cancer , metastasis , stage (stratigraphy) , retrospective cohort study , resection , cancer , paleontology , biology
Objective: The aim of this study was to describe and evaluate the safety of hepatic resections for ovarian cancer liver metastases and the benefit in terms of survival as part of cytoreductive surgery among peritoneal seeding and parenchymal metastases. Materials and Methods: Data were reviewed retrospectively from patients who underwent liver resection as part of cytoreductive surgery for ovarian cancer at the Instituto Nacional de Enfermedades Neoplásicas, in Lima, Perú, from January 2009 to December 2017. Results: From January 2009 to December 2017, 1211 patients underwent surgical cytoreduction for ovarian cancer; 39 of these patients had liver resection as part of their surgical treatment, with 9, 17, and 13 patients receiving primary, secondary, and tertiary, resections, respectively. The mean age of the patients was 46, the majority (87%) had stage III/IV ovarian cancer. In addition, 21 patients had parenchymal metastasis resections, and 95% of the patients had Dindo-Clavien I and II grade complications. The 30-day mortality rate was 0. Conclusions: Liver resection for advanced ovarian cancer is a safe procedure for primary up to quaternary cytoreduction and may confer survival benefits to patients.